A Phase I Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Preservative Free Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients Diagnosed With Glaucoma or Ocular Hypertension

Trial Profile

A Phase I Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Preservative Free Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients Diagnosed With Glaucoma or Ocular Hypertension

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Tafluprost (Primary)
  • Indications Glaucoma; Ocular hypertension
  • Focus Pharmacokinetics
  • Sponsors Santen Oy
  • Most Recent Events

    • 09 Oct 2017 Status changed from recruiting to completed.
    • 25 Jul 2017 This study has been completed in Poland (end date:2017-06-05), according to European Clinical Trials Database.
    • 14 Jul 2017 This study has been completed in Hungary as per European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top